Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Statkevich

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|October 12, 2012
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDa Zhang, Monica Mita, Geoffrey I Shapiro, et al.
Cancer|July 12, 2007
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinibJorge Cortes, Elias Jabbour, George Q Daley, et al.
Current Medical Research and Opinion|June 18, 2004
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatinTeddy Kosoglou, Paul Statkevich, Ingo Meyer, et al.
European Journal of Clinical Pharmacology|April 25, 2012
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairmentPaul Statkevich, Teddy Kosoglou, Richard A Preston, et al.
Journal of Translational Medicine|October 18, 2013
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJohn J Nemunaitis, Karen A Small, Paul Kirschmeier, et al.
Journal of Clinical Pharmacology|August 26, 2016
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid TumorsShruti Agrawal, Paul Statkevich, Gaurav Bajaj, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibeTeddy Kosoglou, Paul Statkevich, Jean-Charles Fruchart, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Cancer Chemotherapy and Pharmacology|July 31, 2009
Evaluation of the exposure equivalence of oral versus intravenous temozolomideBlanca D Diez, Paul Statkevich, Yali Zhu, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|October 12, 2012
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDa Zhang, Monica Mita, Geoffrey I Shapiro, et al.
Cancer|July 12, 2007
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinibJorge Cortes, Elias Jabbour, George Q Daley, et al.
Current Medical Research and Opinion|June 18, 2004
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatinTeddy Kosoglou, Paul Statkevich, Ingo Meyer, et al.
European Journal of Clinical Pharmacology|April 25, 2012
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairmentPaul Statkevich, Teddy Kosoglou, Richard A Preston, et al.
Journal of Translational Medicine|October 18, 2013
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesJohn J Nemunaitis, Karen A Small, Paul Kirschmeier, et al.
Journal of Clinical Pharmacology|August 26, 2016
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid TumorsShruti Agrawal, Paul Statkevich, Gaurav Bajaj, et al.
Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibeTeddy Kosoglou, Paul Statkevich, Jean-Charles Fruchart, et al.
European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.
Cancer Chemotherapy and Pharmacology|July 31, 2009
Evaluation of the exposure equivalence of oral versus intravenous temozolomideBlanca D Diez, Paul Statkevich, Yali Zhu, et al.
Pageof 5